A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade Versus Velcade Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 17 Dec 2021
At a glance
- Drugs Siltuximab (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Centocor; Janssen Research & Development
- 14 Nov 2019 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 07 Nov 2019 Status changed from active, no longer recruiting to completed.
- 02 Aug 2019 According to EUDRA, this trial has been completed in UK(Global end date: 2011-12-01).